Benedikte Hartvigsen

Benedikte Hartvigsen

Auto-generated profile, based on publicly available information

Benedikte Hartvigsen

Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet - Copenhagen University Hospital, Inge Lehmanns Vej 8, 2100 Copenhagen, Denmark; Copenhagen Academy for Medical Education and Simulation, Ryesgade 53B, 2100 Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
BHBenedikte Hartvigsen
Benedikte Hartvigsen
KJKathrine Kronberg Jakobsen
Kathrine Kronberg Jakobsen
TBThomas Benfield
Thomas Benfield
NGNiels Tobias Gredal
Niels Tobias Gredal
AEAnnette Kjær Ersbøll
Annette Kjær Ersbøll
Tobias TodsenTobias Todsen
Tobias Todsen
Background: Testing for SARS-CoV-2 is essential to provide early COVID-19 treatment for people at high risk of severe illness and to limit the spread of infection in society. Proper upper respiratory specimen collection is the most critical step in the diagnosis of the SARS-CoV-2 virus in public settings, and throat swabs were the preferred specimens used for mass testing in many countries during the COVID-19 pandemic. However, there is still a discussion about whether throat swabs have a high enough sensitivity for SARS-CoV-2 diagnostic testing, as previous studies have reported a large variability in the sensitivity from 52% to 100%. Many previous studies exploring the diagnostic accuracy of throat swabs lack a detailed description of the sampling technique, which makes it difficult to compare the different diagnostic accuracy results. Some studies perform a throat swab by only collecting specimens from the posterior oropharyngeal wall, while others also include a swab of the palatine tonsils for SARS-CoV-2 testing. However, studies suggest that the palatine tonsils could have a tissue tropism for SARS-CoV-2 that may improve the SARS-CoV-2 detection during sampling. This may explain the variation of sensitivity reported, but no clinical studies have yet explored the differences in sensitivity and patient discomfort whether the palatine tonsils are included during the throat swab or not. Objective: The objective of this study is to examine the sensitivity and patient discomfort of a throat swab including the palatine tonsils compared to only swabbing the posterior oropharyngeal wall in molecular testing for SARS-CoV-2. Methods: We will conduct a randomized controlled study to compare the molecular detection rate of SARS-CoV-2 by a throat swab performed from the posterior oropharyngeal wall and the palatine tonsils (intervention group) or the posterior oropharyngeal wall only (control group). Participants will be randomized in a 1:1 ratio. All participants fill out a baseline questionnaire upon enrollment in the trial, examining their reason for being tested, symptoms, and previous tonsillectomy. A follow-up questionnaire will be sent to participants to explore the development of symptoms after testing. Results: A total of 2315 participants were enrolled in this study between November 10, 2022, and December 22, 2022. The results from the follow-up questionnaire are expected to be completed at the beginning of 2024. Conclusions: This randomized clinical trial will provide us with information about whether throat swabs including specimens from the palatine tonsils will improve the diagnostic sensitivity for SARS-CoV-2 molecular detection. These results can, therefore, be used to improve future testing recommendations and provide additional information about tissue tropism for SARS-CoV-2. Trial Registration: ClinicalTrials.gov NCT05611203; https://clinicaltrials.gov/study/NCT05611203 International Registered Report Identifier (IRRID): DERR1-10.2196/47446

21 March 2023 in JMIR Preprints
Verified
Preprint
Open access
BHBenedikte Hartvigsen
Benedikte Hartvigsen
KJKathrine Kronberg Jakobsen
Kathrine Kronberg Jakobsen
TBThomas Benfield
Thomas Benfield
NGNiels Tobias Gredal
Niels Tobias Gredal
AEAnnette Kjær Ersbøll
Annette Kjær Ersbøll
Tobias TodsenTobias Todsen
Tobias Todsen
BACKGROUND Testing for SARS-CoV-2 is essential to provide early COVID-19 treatment for people at high risk of severe illness and to limit the spread of infection in society. Proper upper respiratory specimen collection is the most critical step in the diagnosis of the SARS-CoV-2 virus in public settings, and throat swabs were the preferred specimens used for mass testing in many countries during the COVID-19 pandemic. However, there is still a discussion about whether throat swabs have a high enough sensitivity for SARS-CoV-2 diagnostic testing, as previous studies have reported a large variability in the sensitivity from 52% to 100%. Many previous studies exploring the diagnostic accuracy of throat swabs lack a detailed description of the sampling technique, which makes it difficult to compare the different diagnostic accuracy results. Some studies perform a throat swab by only collecting specimens from the posterior oropharyngeal wall, while others also include a swab of the palatine tonsils for SARS-CoV-2 testing. However, studies suggest that the palatine tonsils could have a tissue tropism for SARS-CoV-2 that may improve the SARS-CoV-2 detection during sampling. This may explain the variation of sensitivity reported, but no clinical studies have yet explored the differences in sensitivity and patient discomfort whether the palatine tonsils are included during the throat swab or not. OBJECTIVE The objective of this study is to examine the sensitivity and patient discomfort of a throat swab including the palatine tonsils compared to only swabbing the posterior oropharyngeal wall in molecular testing for SARS-CoV-2. METHODS We will conduct a randomized controlled study to compare the molecular detection rate of SARS-CoV-2 by a throat swab performed from the posterior oropharyngeal wall and the palatine tonsils (intervention group) or the posterior oropharyngeal wall only (control group). Participants will be randomized in a 1:1 ratio. All participants fill out a baseline questionnaire upon enrollment in the trial, examining their reason for being tested, symptoms, and previous tonsillectomy. A follow-up questionnaire will be sent to participants to explore the development of symptoms after testing. RESULTS A total of 2315 participants were enrolled in this study between November 10, 2022, and December 22, 2022. The results from the follow-up questionnaire are expected to be completed at the beginning of 2024. CONCLUSIONS This randomized clinical trial will provide us with information about whether throat swabs including specimens from the palatine tonsils will improve the diagnostic sensitivity for SARS-CoV-2 molecular detection. These results can, therefore, be used to improve future testing recommendations and provide additional information about tissue tropism for SARS-CoV-2. CLINICALTRIAL ClinicalTrials.gov NCT05611203; https://clinicaltrials.gov/study/NCT05611203 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/47446

29 October 2025 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Open access
BHBenedikte Hartvigsen
Benedikte Hartvigsen
KJKathrine Kronberg Jakobsen
Kathrine Kronberg Jakobsen
TBThomas Benfield
Thomas Benfield
NGNiels Tobias Gredal
Niels Tobias Gredal
AEAnnette Kjær Ersbøll
Annette Kjær Ersbøll
TTTobias Todsen
Tobias Todsen
In many jurisdictions, throat swab is the standard specimen for molecular testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and billions of tests have been performed worldwide to date. Despite differing opinions on the diagnostic value of including sample material from the palatine tonsils when performing the throat swab, no studies have investigated the effect on the detection rate of SARS-CoV-2. A randomized controlled trial was conducted in two public test centers for SARS-CoV-2 in Denmark. Participants were invited to participate in the trial due to either symptoms of upper airway infections or screening purposes. The trial took place from November 10 through December 22, 2022. Participants were randomized into two groups in a 1:1 ratio; one group receiving a throat swab of the posterior oropharyngeal wall only and the other group receiving a throat swab of the posterior oropharyngeal wall including the palatine tonsils. All participants filled out a baseline questionnaire, including discomfort with the test. The main outcome was reverse transcription polymerase chain reaction (RT-PCR) test result with a cycle threshold value <38 considered positive and ≥ 38 negative. Overall, 2,315 participants enrolled in the study. In the control group, 29.2% of 1157 enrolled had a positive SARS-CoV-2 test for COVID-19, while 29.8% of 1158 enrolled in the tonsil group had a positive test (OR 0.97, 95% CI 0.84;1.13). The tonsil group reported a mean discomfort score of 0.27 points higher on a 11-point Numerical Rating Scale compared to the control group (95% CI 0.06;0.49). Including the palatine tonsils in throat swabs does not increase the detection rate for SARS-CoV-2, but is associated with more discomfort compared to throat swabs avoiding the palatine tonsils.